Business Context and Reporting Period
This Form 8-K is filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) with a report date of August 11, 2011. The filing addresses a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. However, it notes that the previous auditor's report for the period ended December 31, 2010, included an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern.
Material Changes
- Dismissal of Auditor: Effective August 11, 2011, the Company dismissed Q Accountancy Corporation (QAC), which served as the independent auditor from March 30, 2010, to July 31, 2011.
- Appointment of New Auditor: Effective August 11, 2011, the Company engaged Paritz & Company, P.A. as its new independent registered accounting firm for the fiscal year ending December 31, 2011.
- Internal Control Weakness: The Company previously disclosed a material weakness in internal control over financial reporting due to a lack of proper segregation of duties regarding cash and disbursements, attributed to very limited staff.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance or management commentary regarding future financial performance. The primary risk highlighted is the going concern uncertainty noted by the former auditor. The Company states there were no disagreements with QAC regarding accounting principles, financial statement disclosures, or auditing scope during the period, except for the noted material weakness which was disclosed without disagreement.
Investor Verification Checklist
- Verify the reasons for the auditor change beyond the stated lack of disagreements.
- Review the most recent financial statements to assess the current status of the "going concern" warning.
- Confirm the implementation of compensating procedures for the disclosed material weakness in internal controls.
- Examine the letter from Q Accountancy Corporation (Exhibit 16.1) for any additional context regarding the dismissal.